We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
19/6/2023 14:17 | I'm enjoying the ride but we are now at a price that suggests the probability of success in the in vitro trials is rising. RENE has failed with two products in the past. Fingers crossed for 3rd time lucky rather than 3rd strike and you're out. | dickbush | |
16/6/2023 16:42 | so theyve spent about 12k each laughable | fred177 | |
16/6/2023 16:29 | Share Purchase by Senior Independent Non-executive Director ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that Barbara Staehelin, Senior Independent Non-executive Director of the Company, has today purchased 150,000 of the Company's ordinary shares of 1p each ("Ordinary Shares"). | xow98 | |
16/6/2023 13:32 | Share Purchase by Executive Chairman ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , announces that Iain Ross, Executive Chairman of the Company, has today purchased 150,000 of the Company's ordinary shares of 1p each ("Ordinary Shares"). | xow98 | |
26/5/2023 13:45 | Seems the 'investormeet' went down swimmingly. | glavey | |
25/5/2023 21:13 | IMC today. "Reneuron is NOT going bust" "£35m fair value in the analyst report" Current market cap - £3.6m | nigelpm | |
25/5/2023 13:02 | However, there is no guarantee that attempts to secure adequate cash inflows from the Group's exosome platform, IP and legacy assets or through equity fund raising with the timescales stated above will be successful. These conditions indicate the existence of a material uncertainty, which may cast significant doubt about the Group's and Company's ability to continue as a going concern. | terminator101 | |
25/5/2023 12:14 | It looks like Obotritia Capital is providing a tap. I just bought some at very close to the bid price. It's marked as a sale. | dickbush | |
25/5/2023 08:17 | Switched to HARL at good time | blackhorse23 | |
25/5/2023 08:16 | Require placing or bust | blackhorse23 | |
25/5/2023 06:36 | You reading the same results as me?? | babbler | |
25/5/2023 06:19 | Horror show results. Fundraising incoming. | terminator101 | |
23/5/2023 08:51 | Agreed. Money you can lose. But could be good. | richtea2517 | |
18/5/2023 09:28 | Investor presentation ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell derived exosome technologies , will announce its preliminary results for the year ended 31 March 2023 on Thursday 25 May 2023. Investor Briefing Management will also be hosting a live online presentation relating to the preliminary results via the Investor Meet Company platform at 9:30am BST on Thursday 25 May 2023. The presentation is open to all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and register for the presentation here: Investors who already follow ReNeuron on the Investor Meet Company platform will automatically be invited. Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. | thiopia | |
16/5/2023 20:57 | That's exactly the punt - a large one but could come off. | nigelpm | |
16/5/2023 18:24 | This now looks interesting. Market cap of £4m and holds cash of around £6m. Some recent buying by Directors and NED. They have a cash runway into 2024 to be able to commercialise their exosome platform. Share price about 7p and brokers have targets around 70p. Seems high risk / high reward opportunity? I have made a small investment today that I am prepared to lose 100% of it. Be interesting to see what happens over the next 6 to 9 months. | pdt | |
06/5/2023 17:01 | Just checking in on this pile of lifestyle scientist pedestrian pish. Plus ca change huh. Zzzzzzzzzzz | terminator101 | |
06/4/2023 15:26 | Wow mom exec director spends 4.5 k on shares must be about to fly NOT at least put your full new ISA allowance if you have any confidence at all which I don’t | fred177 | |
28/3/2023 13:48 | Seems that Ross' purchase today showing as a sell. Encouraging confidence though. | small crow | |
03/3/2023 16:14 | Just bought OK | red army | |
03/3/2023 15:53 | Trying to buy but seems not much for sale. | small crow |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions